A phase II clinical trial in China tested engineered immune cells known as CAR-T cells on patients with advanced gastric cancer. The clinical trial yielded impressive results, demonstrating that altered T cells can target solid tumors effectively, which has historically been challenging. Of the 156 participants, 35% responded positively to the satricabtagene autoleucel (satri-cel), compared to only 4% from standard treatments. This trial represents a significant advancement in the potential of immunotherapy for solid tumors, offering hope for more effective treatments in cancer care.
The results show that CAR-T-cell therapy can significantly improve survival rates in patients with solid tumors, a milestone in cancer treatment.
The trial highlights the potential of CAR-T-cell therapy, traditionally successful in blood cancers, to be adapted for solid tumors.
Collection
[
|
...
]